Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia

Published:2024-04 Issue:4 Volume:25 Page:413-414
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yang Lin,Banerji Versha

Publisher

Elsevier BV

Reference10 articles.

1. Initial treatment of CLL: integrating biology and functional status;Jain;Blood,2015

2. Impact of fixed-duration oral targeted therapies on the economic burden of chronic lymphocytic leukemia in Canada;Lachaine;Curr Oncol,2023

3. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia;Banerji;Curr Oncol,2020

4. The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives;Eyre;Cancers (Basel),2023

5. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations;Tambaro;Lancet Haematol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3